Drugs / Ossium vBM-MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05075811 | Feb 2022 → Nov 2024 | intestinal fistula, small intestine disorder | Anthony Lembo | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ossium vBM-MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05075811 ↗ |
| Modality | Cell therapy | “allogeneic bone marrow derived mesenchymal stem cells (MSCs)” NCT05075811 ↗ |
| Route | Other | “Direct injection of vertebral bone marrow derived mesenchymal stem cells” NCT05075811 ↗ |